Maura E Walker1, Vanessa Xanthakis1,2,3, Lynn L Moore1, Ramachandran S Vasan1,3,4, Paul F Jacques5. 1. Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. 2. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. 3. Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA. 4. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 5. Nutritional Epidemiology, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Abstract
BACKGROUND: Ceramides have been implicated in the pathogenesis of type 2 diabetes and cardiovascular disease. Limited data exist on how habitual dietary intake of foods that can alter hepatic lipid metabolism may influence circulating ceramide concentrations. OBJECTIVES: We investigated the cross-sectional association of cumulative sugar-sweetened beverage (SSB) consumption with concentrations of 3 circulating ceramides and ceramide ratios. METHODS: We examined participants from the Framingham Heart Study's Offspring Cohort who had 3 ceramides measured (n = 1561, mean age 66 y, 59% women). SSB consumption was measured 4 times over ∼14 y. Participants were categorized by cumulative SSB intake as nonconsumers (0 to <1 SSB serving/mo) and occasional (1 SSB serving/mo to <1 serving/wk), frequent (1 SSB serving/wk to <1 serving/d), and daily (≥1 SSB serving/d) consumers. Multivariable linear regression models were used to relate cumulative SSB consumption (independent variable) to blood concentrations of ceramides (C16:0, C22:0, and C24:0) and ceramide ratios (C22:0/C16:0 and C24:0/C16:0). RESULTS: In adjusted models, more frequent cumulative SSB consumption was positively associated with concentrations of the C16:0 and C22:0 ceramides (Ptrend < 0.05). Compared with nonconsumers, daily consumers had 0.01 μg/mL (95% CI: 0.002, 0.017 µg/mL) and 0.06 µg/mL (95% CI: 0.018, 0.092 µg/mL) higher mean concentrations of the C16:0 and C22:0 ceramides, respectively. Results were consistent when modeling continuous cumulative SSB consumption per 1 serving/d. We observed effect modification by diabetes status in the relation between cumulative SSB consumption and concentrations of the C24:0 ceramide (Pinteraction = 0.014). In a stratified analysis, more frequent cumulative SSB consumption was positively associated with concentrations of the C24:0 ceramide only in individuals with prediabetes or diabetes (Ptrend = 0.001). CONCLUSIONS: Our study raises the possibility that higher concentrations of distinct ceramide species, previously associated with adverse metabolic health, may be one mechanism by which SSB consumption contributes to higher risk of cardiometabolic diseases.
BACKGROUND:Ceramides have been implicated in the pathogenesis of type 2 diabetes and cardiovascular disease. Limited data exist on how habitual dietary intake of foods that can alter hepatic lipid metabolism may influence circulating ceramide concentrations. OBJECTIVES: We investigated the cross-sectional association of cumulative sugar-sweetened beverage (SSB) consumption with concentrations of 3 circulating ceramides and ceramide ratios. METHODS: We examined participants from the Framingham Heart Study's Offspring Cohort who had 3 ceramides measured (n = 1561, mean age 66 y, 59% women). SSB consumption was measured 4 times over ∼14 y. Participants were categorized by cumulative SSB intake as nonconsumers (0 to <1 SSB serving/mo) and occasional (1 SSB serving/mo to <1 serving/wk), frequent (1 SSB serving/wk to <1 serving/d), and daily (≥1 SSB serving/d) consumers. Multivariable linear regression models were used to relate cumulative SSB consumption (independent variable) to blood concentrations of ceramides (C16:0, C22:0, and C24:0) and ceramide ratios (C22:0/C16:0 and C24:0/C16:0). RESULTS: In adjusted models, more frequent cumulative SSB consumption was positively associated with concentrations of the C16:0 and C22:0 ceramides (Ptrend < 0.05). Compared with nonconsumers, daily consumers had 0.01 μg/mL (95% CI: 0.002, 0.017 µg/mL) and 0.06 µg/mL (95% CI: 0.018, 0.092 µg/mL) higher mean concentrations of the C16:0 and C22:0 ceramides, respectively. Results were consistent when modeling continuous cumulative SSB consumption per 1 serving/d. We observed effect modification by diabetes status in the relation between cumulative SSB consumption and concentrations of the C24:0 ceramide (Pinteraction = 0.014). In a stratified analysis, more frequent cumulative SSB consumption was positively associated with concentrations of the C24:0 ceramide only in individuals with prediabetes or diabetes (Ptrend = 0.001). CONCLUSIONS: Our study raises the possibility that higher concentrations of distinct ceramide species, previously associated with adverse metabolic health, may be one mechanism by which SSB consumption contributes to higher risk of cardiometabolic diseases.
Authors: Dong D Wang; Estefanía Toledo; Adela Hruby; Bernard A Rosner; Walter C Willett; Qi Sun; Cristina Razquin; Yan Zheng; Miguel Ruiz-Canela; Marta Guasch-Ferré; Dolores Corella; Enrique Gómez-Gracia; Miquel Fiol; Ramón Estruch; Emilio Ros; José Lapetra; Montserrat Fito; Fernando Aros; Luis Serra-Majem; Chih-Hao Lee; Clary B Clish; Liming Liang; Jordi Salas-Salvadó; Miguel A Martínez-González; Frank B Hu Journal: Circulation Date: 2017-03-09 Impact factor: 29.690
Authors: Ravi Dhingra; Lisa Sullivan; Paul F Jacques; Thomas J Wang; Caroline S Fox; James B Meigs; Ralph B D'Agostino; J Michael Gaziano; Ramachandran S Vasan Journal: Circulation Date: 2007-07-23 Impact factor: 29.690
Authors: Maija Ruuth; Su Duy Nguyen; Terhi Vihervaara; Mika Hilvo; Teemu D Laajala; Pradeep Kumar Kondadi; Anton Gisterå; Hanna Lähteenmäki; Tiia Kittilä; Jenni Huusko; Matti Uusitupa; Ursula Schwab; Markku J Savolainen; Juha Sinisalo; Marja-Liisa Lokki; Markku S Nieminen; Antti Jula; Markus Perola; Seppo Ylä-Herttula; Lawrence Rudel; Anssi Öörni; Marc Baumann; Amos Baruch; Reijo Laaksonen; Daniel F J Ketelhuth; Tero Aittokallio; Matti Jauhiainen; Reijo Käkelä; Jan Borén; Kevin Jon Williams; Petri T Kovanen; Katariina Öörni Journal: Eur Heart J Date: 2018-07-14 Impact factor: 29.983
Authors: Linda R Peterson; Vanessa Xanthakis; Meredith S Duncan; Stefan Gross; Nele Friedrich; Henry Völzke; Stephan B Felix; Hui Jiang; Rohini Sidhu; Matthias Nauck; Xuntian Jiang; Daniel S Ory; Marcus Dörr; Ramachandran S Vasan; Jean E Schaffer Journal: J Am Heart Assoc Date: 2018-05-03 Impact factor: 5.501
Authors: Sagar B Dugani; Luke R Christenson; Jeremiah A Aakre; Hai H Bui; Adrian Vella; Michelle M Mielke Journal: Diabetes Res Clin Pract Date: 2021-07-29 Impact factor: 8.180
Authors: Emily Olson; Jung H Suh; Jean-Marc Schwarz; Susan M Noworolski; Grace M Jones; John R Barber; Ayca Erkin-Cakmak; Kathleen Mulligan; Robert H Lustig; Michele Mietus-Snyder Journal: Nutrients Date: 2022-03-30 Impact factor: 6.706